• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Health Tech Firms Ultromics and Caption Health Partner to Tackle Cardiac Disease

Share:

November 23, 2021

UK-based health tech firm Ultromics and Caption Health today announced a partnership to accelerate cardiovascular disease detection and treatment for more patients inaccessible care settings.

The companies, which both specialize in using AI to improve heart ultrasound diagnostics, will offer Caption Health’s AI software platform alongside Ultromics’ EchoGo deep ultrasound analytics.

Through the collaboration, they aim to empower clinicians with AI-enhanced diagnostics for heart failure and coronary artery disease beyond the hospital setting. This will enable a broader set of providers to perform ultrasounds and automatically calculate key indicators of heart function which drive earlier and more accurate disease diagnoses.

WHY IT MATTERS

Access to proper cardiac health care is a global problem, leading to countless preventable deaths.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

A limited number of specialists are available to perform and analyze cardiac ultrasounds – a key diagnostic procedure for identifying the beginning or progression of heart failure, valve disease, and coronary artery disease.

By linking their platforms, images acquired using Caption AI can be analysed through Ultromics’ EchoGo platform, expanding access to advanced diagnostic capabilities to doctors and patients in more places.

THE LARGER CONTEXT

Oxford University spinout, Ultromics announced a raise of $33 million (£24.3m) in Series B funding earlier this year. The firm has previously partnered with leading research institutions, including the Mayo Clinic, the NHS, and the American Society of Echocardiography.

According to a recent study published in Aha Journals, 46% of patients in the US diagnosed with heart failure in acute care settings had potential symptoms at primary care clinic visits in the previous six months. These issues were also more prevalent among women and black patients.

Meanwhile, the UK government recently announced £5.9 billion to help clear treatment backlogs and improve diagnostic service in the NHS, reflecting the great need exacerbated by COVID-19.

ON THE RECORD

Steve Cashman, president, and CEO of Caption Health said: “More efficiently delivered and robust patient care is a necessity for the healthcare system to really improve. This means empowering the entire care team and making diagnostics a key part of the care that’s more accessible to patients.

“With Ultromics’ enhanced analysis complementing Caption AI, providers will be able to capture images earlier and get more out of those images, maximizing benefits for patients. Together, we’ll help drive the move to earlier detection and diagnosis of cardiac disease in patients—enabling proper management alongside more cost-efficient and timely care.”

Ross Upton, founder, and CEO of Ultromics, said: “EchoGo is already delivering to experts an expansive set of fully automated, advanced clinical analysis and diagnostic support modules.

“Caption Health will carry our platform beyond the walls of the imaging lab, allowing new providers with less experience the ability to perform diagnostic ultrasounds and gain advanced measurements of cardiac function and diagnostic support, for earlier and more accessible detection of cardiovascular disease.”

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Aileron Therapeutics Announces Acquisition of Lung TherapeuticsAileron Therapeutics Announces Acquisition of Lung Therapeutics
  • Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsAdamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
  • Sagard Healthcare Royalty Partners and Newcastle University, UK Announce the Monetization of Royalty Interest in Cancer Drug, RubracaSagard Healthcare Royalty Partners and Newcastle University, UK Announce the Monetization of Royalty Interest in Cancer Drug, Rubraca
  • ZOLL Announces Closing of Acquisition of Itamar MedicalZOLL Announces Closing of Acquisition of Itamar Medical
  • Aya Healthcare Acquires Symmetry Healthcare Solutions, Expands Vendor Neutral DivisionAya Healthcare Acquires Symmetry Healthcare Solutions, Expands Vendor Neutral Division
  • Neutra Executes LOI to Acquire Private Clinical Research Site Management OrganizationNeutra Executes LOI to Acquire Private Clinical Research Site Management Organization
  • Lilly Announces Agreement To Acquire Loxo OncologyLilly Announces Agreement To Acquire Loxo Oncology
  • Aurora Cannabis to buy remaining interest in Hempco Food and FiberAurora Cannabis to buy remaining interest in Hempco Food and Fiber

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications